Low bioavailability of rectally administered thalidomide

American Journal of Health-System Pharmacy

Volumn 57, Issue 17, 2000, Pages 1607-1610

  Eriksson, Tommy ^a   Wallin, Ronnie ^b   Höglund, Peter ^c   Roth, Bodil ^d   Qi, Zhongquan ^e   Östraat, Öyvind ^f   Björkman, Sven ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Galenica AB   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d MUH   (Sweden)

^e Sahlgrenska University Hospital ^*  (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ELDEXOMER; EXCIPIENT; LICHROSOLV; TETRAHYDROFURAN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEDATION; SUPPOSITORY; SWEDEN; TABLET;

EID: 0034284763     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.17.1607     Document Type: Article

References (12)

1. Schuler S, Ehninger U. Thalidomide: rationale for renewed use in immunological disorders. Drug Saf. 1995; 12:364-9.
2. Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations. J Inflamm. 1996; 46:177-211.
3. Hague D, Smith RL. Enigmatic properties of (±) thalidomide; an example of a stable racemic compound. Br J Clin Pharm. 1988; 26:623.
4. Eriksson T, Björkman S, Fyge Å et al. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr Biomed Appl. 1992; 582:211-6.
5. Eriksson T, Björkman S. Handling of blood samples for determination of thalidomide. Clin Chem. 1997; 43: 1095-6.
6. Eriksson T, Björkman S, Roth B et al. Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J Pharm Pharmacol. 1999; 50:1409-16.
7. Heney D, Norfolk DR, Wheeldon J et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol. 1991; 78:23-7.
8. Boughton BJ, Sheehan TMT, Wood J et al. High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem. 1995; 32:79-83.
9. Eriksson T, Björkman S, Roth B et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality. 1995; 7:44-52.
10. Budavari S, ed. The Merck index. 12th ed. White House Station, NJ: Merck; 1996.
11. The United States pharmacopeia, 23rd rev., and The national formulary, 18th ed. Rockville, MD: United States Pharmacopeial Convention; 1994: 1791-3.
12. Nuevonen PJ, Pentikäinen PJ, Elfving SM. Factors affecting the bioavailability of phenytoin. Int J Pharmacol. 1977; 15:84-9.